Novel statistical tools for monitoring the safety of marketed drugs (Q36835511)

16 August 2017

1 reference

title

Novel statistical tools for monitoring the safety of marketed drugs (English)

1 reference

16 August 2017

0 references

J S Almenoff

1

1 reference

16 August 2017

E N Pattishall

2

1 reference

16 August 2017

T G Gibbs

3

1 reference

16 August 2017

W DuMouchel

4

1 reference

16 August 2017

S J W Evans

5

1 reference

16 August 2017

N Yuen

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

30 May 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

1 reference

16 August 2017

82

1 reference

16 August 2017

2

1 reference

16 August 2017

157-166

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100258

16 August 2017

0 references

cites work

Why there is a need for pharmacovigilance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Principles of signal detection in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Causal or casual? The role of causality assessment in pharmacovigilance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Does proof of casualty ever exist in pharmacovigilance?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Time to act on drug safety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Perspectives on the use of data mining in pharmaco-vigilance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Statistical techniques for signal generation: the Australian experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

A Bayesian neural network method for adverse drug reaction signal generation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Practical pharmacovigilance analysis strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Pharmacovigilance in the 21st century: new systematic tools for an old problem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

A brief primer on automated signal detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Impact analysis of signals detected from spontaneous adverse drug reaction reporting data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Abstracts of the 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, 22-25 August 2004

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Clinical pharmacokinetics of allopurinol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Data quality management in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Using MedDRA: implications for risk management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

The general practice research database: role in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100258

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100258

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference